ANZCHOG

Recent papers from ANZCHOG

1. Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoformsExperimental Hematology and Oncology · 2026
2. Clinical evidence and biological mechanisms linking obesity to adverse outcomes in pediatric and adolescent acute lymphoblastic leukemiaFrontiers in Oncology · 2026
3. Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALLPediatric Blood & Cancer · 2026
4. The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic LeukemiaNeoplasia · 2026
5. Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapyLeukemia · 2026
6. The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemiaGut Pathogens · 2026
7. ID #672 A phase II study of continuous low dose panobinostat in paediatric patients with atypical teratoid rhabdoid tumours (ATRT).Neuro-Oncology Pediatrics · 2026
8. ID #354 Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of VInblastine in Combination with TOvorafenib in Recurrent/progressive low-grade glioma children and Young adults (VICTORY): Results from Phase A of a Canadian/Australian studyNeuro-Oncology Pediatrics · 2026
9. ID #112 PAEDNEOVAX - Multicentre, investigator-initiated phase I/II study to assess safety and efficacy of personalised mRNA vaccine targetting tumour-associated neoantigens in children and young adults with high-risk brain tumours.Neuro-Oncology Pediatrics · 2026
10. Biological and clinical characteristics of ETV6 :: RUNX1 ‐like ALLHemaSphere · 2026
11. Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.2026
12. High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to LarotrectinibPediatric Blood & Cancer · 2025
13. The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in ABL -rearranged ALL2025
14. Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domainBlood Neoplasia · 2025
15. Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin InhibitorCancers · 2024
16. Path-02. The Impact of Evolving Diagnostic Methodology on the Classification and Outcome of Central Nervous System Tumours in Childhood: A Retrospective Cohort StudyNeuro-Oncology · 2024
17. Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia PatientsCancers · 2023
18. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanismScientific Reports · 2023
19. Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System TumorsJournal of Molecular Diagnostics · 2023
20. Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expressionFrontiers in Oncology · 2023